Company intelligence / Profile preview

RoC

Ownership: Private
Development stage: Commercial

Overview

Lead program RR-M01 in clinical trials as of 2024, has completed drug administration assessment for multiple subjects with good safety and efficacy signals. Focused on malignant solid tumors including ovarian cancer, expanding indications to all HER2-positive or low-expression solid tumors. Additional clinical trials ongoing/planned for pancreatic/prostate/small cell lung cancers.

Therapeutic areas: OncologyRare Diseases
Modalities: Cell therapyGene editing
Industry: Biotech

Drug pipeline

2 assets

Barrier Renew

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Affiliated Hospital of Xuzhou Medical University (clinical trial partner)International collaboration with Armenia on rare disease research

Beyond the preview

Go deeper on RoC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RoC.

Explore the full profile